Showing 2571-2580 of 9112 results for "".
Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.Strategies for Success: Tips on Running a Successful Dermatology Practice
https://practicaldermatology.com/conferences/scale-2023/strategies-for-success-tips-on-running-a-successful-dermatology-practice/20199/Mark D. Kaufmann, MD, Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery Clinics, discusses what it takes to run a successful dermatology practice today, including the importance of leveraging data to prove value and sharpening business skills.DermWireTV: Skyrizi for PsA; Toxins and Wound Healing at Maui Derm; SDDS Registration
https://practicaldermatology.com/topics/psoriasis/skyrizi-for-psa-toxins-and-wound-healing-at-maui-derm-sdds-registration-dermwiretv/20057/Skyrizi (AbbVie) is now approved for the treatment of adults with active psoriatic arthritis. Michael Gold, MD was among the speakers who offered updates on cosmetic trends as well as medical care at Maui Dermatology for Dermatologists last week. He spoke about high-dose neurotoxins. Robert KirsnerA Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.Quarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andCOVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do notOffering Patients a Clean Slate with PicoWay
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/offering-patients-a-clean-slate-with-picoway/18656/Vic Narurkar, MD shares his work with Project New Start and helping high-risk youth with gang-related tattoos get a new start. Through the program, which Syneron-Candela helps to support, physicians volunteer to remove tattoos and help these patients turn their lives around through community serviceNewDerm LIVE: Update
https://practicaldermatology.com/topics/practice-management/newderm-live-update/18844/NewDerm LIVE is coming! September 18-20, 2015 at the W Hollywood, CA. Faculty member Neal Bhatia, MD talks to program co-chairs Peter Lio, MD about the goals of the meeting, the agenda, and exciting plans for the weekend. It's not too late to be part of this one-of-a-kind event. Register nowThe Mechanism of Itch
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37155/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses the mechanism of itch and how that understanding should influence treating patients wiTargeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseases